GSK plc (NYSE:GSK) Shares Sold by Eversept Partners LP

Eversept Partners LP lowered its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 9.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,661,768 shares of the pharmaceutical company's stock after selling 395,438 shares during the quarter. GSK accounts for about 11.0% of Eversept Partners LP's portfolio, making the stock its 2nd biggest position. Eversept Partners LP owned about 0.18% of GSK worth $123,841,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Indiana Trust & Investment Management Co raised its holdings in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Crews Bank & Trust acquired a new stake in GSK in the 4th quarter valued at $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 522 shares in the last quarter. Sierra Ocean LLC acquired a new position in shares of GSK during the 4th quarter worth about $32,000. Finally, Parkside Financial Bank & Trust grew its holdings in shares of GSK by 470.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after acquiring an additional 818 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

GSK Stock Performance

GSK stock traded down $0.08 during mid-day trading on Friday, hitting $37.42. 3,909,251 shares of the company were exchanged, compared to its average volume of 4,704,552. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The stock has a market capitalization of $77.21 billion, a PE ratio of 23.53, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The business has a 50 day simple moving average of $37.48 and a 200-day simple moving average of $36.05. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 10th. Investors of record on Friday, February 21st were paid a $0.3932 dividend. The ex-dividend date of this dividend was Friday, February 21st. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.20%. GSK's dividend payout ratio is 100.63%.

Analyst Ratings Changes

Several brokerages recently commented on GSK. Morgan Stanley started coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. BNP Paribas started coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Finally, StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Eight equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.